Compare Aurora Cannabis Inc (ACB) vs Unilever plc (UL) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

Unilever (UL) trades at $62.74, up 0.42% today, with a bullish technical signal from moving averages. Recent earnings misses contrast with strong profitability margins and a 53.32% ROE. The company is actively reshaping its portfolio through deals like the proposed McCormick food business combination and a $270 million innovation center investment, signaling strategic growth initiatives amid mixed quarterly performance.

UL presents a balanced risk-reward with fair valuation metrics, but faces execution risks from recent earnings shortfalls and portfolio transitions. The analyst community is divided, with a slim majority recommending Hold. Investors should weigh strong cash flow generation against competitive pressures in consumer goods markets.